Hyperkalemia, hypomagnesemia, and hyperparathyroidism commonly persist after kidney transplant surgery.
Maintenance hemodialysis patients with SHPT who switched from IV vitamin D analogs to oral calcitriol had similar serum levels of iPTH, calcium, and phosphate at 12 months as those who continued on the IV treatment.
If validated, new study findings may be used to develop a disease-specific patient-reported outcome measure that will inform SHPT treatment.
Parathyroid hormone levels decreased significantly in pediatric dialysis patients with secondary hyperparathyroidism within 1 month of starting cinacalcet, investigators reported.
Parathyroidectomies for kidney transplant recipients with hyperparathyroidism should be timely and without removal of too much parathyroid hormone to avoid steep drops in intact parathyroid hormone, according to investigators.
In a position statement on cinacalcet use in children on dialysis, the authors emphasized avoiding hypocalcemia.
In a study, PTH exceeding 600 pg/mL prior to initiation of dialysis was associated with persistently high PTH in the first year of hemodialysis.
In a study, patients with severe secondary hyperparathyroidism appeared to benefit the most from surgery.
In a study of hemodialysis patients, hypercalcemia accompanied by high parathyroid hormone levels was associated with nearly 2.6-fold increased odds of intradialytic hypotension.
Thermal ablation and parathyroidectomy (PTx) both effectively treat secondary hyperparathyroidism (SHPT), according to research.